Seehra Jasbir
CHIEF EXECUTIVE OFFICER
Seehra Jasbir has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Apr 6, 2026.
On the most recent filing, Seehra Jasbir is listed as CHIEF EXECUTIVE OFFICER at Keros Therapeutics, Inc. Inside the rolling window, Seehra Jasbir reported no open-market purchases and 1 open-market sale totaling $113K in KROS.
Companies traded
Other insiders at KROS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$113K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Seehra Jasbir made?
Seehra Jasbir has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does Seehra Jasbir trade?
Seehra Jasbir has filed SEC Form 4 disclosures for 1 company, including KROS.
When was Seehra Jasbir's most recent SEC Form 4 filing?
Seehra Jasbir's most recent SEC Form 4 filing on Tracefour is dated Apr 6, 2026.
What is Seehra Jasbir's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Seehra Jasbir is listed as CHIEF EXECUTIVE OFFICER.
What is Seehra Jasbir's total buy and sell value in the current window?
Inside the rolling retention window, Seehra Jasbir bought $0 and sold $113K based on SEC Form 4 filings.
What was Seehra Jasbir's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,015 KROS shares on 2026-02-19, worth $113K, per SEC Form 4 filings.